For research use only. Not for therapeutic Use.
PF-04965842 (Cat No.:I011983) is a selective Janus kinase 1 (JAK1) inhibitor developed for the treatment of moderate to severe atopic dermatitis. By inhibiting JAK1, it blocks the signaling pathways of key cytokines involved in inflammation and immune response. This action helps reduce symptoms such as itching, redness, and swelling associated with atopic dermatitis. Abrocitinib has shown efficacy in improving skin condition and overall patient quality of life. Its oral administration provides a convenient alternative to topical treatments for managing chronic skin inflammation.
| Catalog Number | I011983 |
| CAS Number | 1622902-68-4 |
| Synonyms | PF-04965842; PF 04965842; PF04965842;;N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide |
| Molecular Formula | C14H21N5O2S |
| Purity | 98% |
| Target | Stem Cell/Wnt |
| Target Protein | |
| Solubility | Soluble in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | JAK1:29 nM (IC50) |
| IUPAC Name | N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide |
| InChI | InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17) |
| InChIKey | IUEWXNHSKRWHDY-UHFFFAOYSA-N |
| SMILES | CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3 |
| Reference | </br>1: Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, Kieras E, Parsons-Rich D, Menon S, Salganik M, Page K, Peeva E. Efficacy and safety of the Janus Kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2017 Sep 26. doi: 10.1111/bjd.16004. [Epub ahead of print] PubMed PMID: 28949012.</br></br> |
